Cholecalciferol supplementation in HIV-infected youth with vitamin d insufficiency: Effects on vitamin d status and t-cell phenotype: A randomized controlled trial

HIV Clinical Trials

Volumn 14, Issue 2, 2013, Pages 51-60

  Giacomet, Vania ^a   Vigano, Alessandra ^a   Manfredini, Valeria ^a   Cerini, Chiara ^a   Bedogni, Giorgio ^b   Mora, Stefano ^c   Borelli, Manuela ^d   Trabattoni, Daria ^d   Zuccotti, Gian ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Liver Research Center   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

adolescents; children; HIV; immunity; vitamin D

Indexed keywords

COLECALCIFEROL; PARATHYROID HORMONE; PLACEBO; VITAMIN D RECEPTOR; 1,25-DIHYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; CALCITRIOL; DRUG DERIVATIVE; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; BONE METABOLISM; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; BLOOD; CONTROLLED CLINICAL TRIAL; DIET SUPPLEMENTATION; IMMUNOLOGY; IMMUNOPHENOTYPING;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; CHILD; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; HIV INFECTIONS; HUMANS; IMMUNOPHENOTYPING; T-LYMPHOCYTES; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

MLCS; MLOWN;

EID: 84878853303     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1402-51     Document Type: Article

References (49)

1. Zadshir A, Tareen N, Pan D, et al. The prevalence of hypo-vitaminosis D among US adults: data from the NHANES III. Ethn Dis. 2005;15(4 suppl 5):S5-97-101.
2. Bischoff-Ferrari HA. "Vitamin D-why does it matter?" defining Vitamin D deficiency and its prevalence. Scand J Clin Lab Invest. 2012;243(suppl):3-6.
3. Gordon CM, Williams AL, Feldman HA, et al. Treatment of hypovitaminosis D in infants and toddlers. J Clin Endocrinol Metab. 2008;93:2716-2721.
4. Adams JS, Kantorovich V, Wu C, et al. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. J Clin Endocrinol Metab. 1999;84:2729-2730.
5. Aloia J F, Patel M, Dimaano R, et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr. 2008;87:1952-1958.
6. Cesur Y, Caksen H, Gundem A, et al. Comparison of low and high dose of vitamin D treatment in nutritional vitamin D deficiency rickets. J Pediatr Endocrinol. 2003;16: 1105-1109.
7. 3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract. 2008;14:10-17.
8. Dawson-Hughes B, Harris SS. High-dose vitamin D supplementation: too much of a good thing? JAMA. 2000;303:1861-1862.
9. Ilahi M, Armas LA, Heaney R P. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr. 2008;87:688-691.
10. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial [erratum 2010;303:2357]. JAMA. 2010 303:1815-1822.
11. Shah BR, Finberg L. Single-day therapy for nutritional vitamin D-deficiency rickets: a preferred method. J Pediatr. 1994;125:487-490.
12. Khazai NB, Judd SE, Jeng L, et al. Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light. J Clin Endocrinol Metab. 2009;94:2037-2043.
13. Kuehn EW, Anders HJ, Bogner JR, et al. Hypocalcaemia in HIV infection and AIDS. J Intern Med. 1999;245:69-73.
14. Rodriguez M, Daniels B, Gunawardene S, et al. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses. 2009;25:9-14.
15. Stephensen CB, Marquis GS, Kruzich LA, et al. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr. 2006;83:1135-1141.
16. Rutstein R, Downes A, Zemel B, et al. Vitamin D status in children and young adults with perinatally acquired HIV infection. Clin Nutr. 2011;30(5):624-628.
17. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1375-1382.
18. Mueller NJ, Fux CA, Ledergerber B, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010;24:1127-1134.
19. Allavena C, Delpierre C, Cuzin L, et al. High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs [published online ahead of print May 15, 2012]. J Antimicrob Chemother.
20. Conesa-Botella A, Florence E, Lynen L, et al. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther. 2010;7:40.
21. Foissac F, Tréluyer JM, Souberbielle JC, et al. Vitamin D3 supplementation scheme in HIV-infected patients based upon a pharmacokinetic modelling of 25-hydroxycholecalciferol [published online ahead of print October 17, 2012]. Br J Clin Pharmacol.
22. 3 supplementation 50.000 IU monthly in youth with HIV-1 infection. J Clin Endocrinol Metab. 2012;97:4004-4013.
23. Arpadi SM, McMahon D, Abrams EJ, et al. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics. 2009;123:e121-126
24. Arpadi SM, McMahon DJ, Abrams EJ, et al. Effect of supplementation with cholecalciferol and calcium on 2-y bone mass accrual in HIV-infected children and adolescents: a randomized clinical trial. Am J Clin Nutr. 2012;95:678-685.
25. 3receptor in the immune system. Arch Biochem Biophys. 2000;374(2):334-338.
26. Sloka S, Silva C, Wang J, et al. Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism. J Neuroinflammation. 2011;24(8):56.
27. Baeke F, Takiishi T, Korf H, et al. Vitamin D: modulator of the immune system. Curr Opin Pharmacol. 2010;10: 482-496.
28. Klein SA, Dobmeyer JM, Dobmeyer TS, et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS. 1997;15;11(9):1111-1118.
29. Holick M F, Binkley NC, Bischoff-Ferrari HA, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930.
30. Haug CJ, Aukrust P, Haug E, et al. Severe deficiency of 1, 25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998;83:3832-3838.
31. Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep. 1994;43(RR-12):1-10.
32. Signorello LB, Shi J, Cai Q, et al. Common variation in vitamin D pathway genes predicts circulating 25-hydroxyvitamin D levels among African Americans. PLoS One. 2011;6(12):e28623.
33. Ryan P. Random allocation of treatments in blocks. Stata J. 2008;8:594.
34. Caputo D, Leone MA, Zanzottera M, et al. Vitamin D receptor (VDR) gene SNPs influence VDR expression and modulate protection from multiple sclerosis in HLA-DRB1*15-positive individuals. Brain Behav Immun. 2011;25(7):1460- 1467.
35. Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis, Hoboken, NJ: Wiley; 2011.
36. Rabe-Hesketh S, Skrondal A. Multilevel and Longitudinal Modeling Using Stata. Volume 1: Continuous Responses. College Station, TX: Stata Press; 2012.
37. Carpenter JR, Kenward MG. Missing data in randomised controlled trials: a practical guide [monograph]. London School of Hygiene & Tropical Medicine; 2007. www. missingdate.org.uk
38. 3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab. 1998;83(11):3832-3838.
39. Teichmann J, Stephan E, Lange U, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect Dis. 2003;46:221-227.
40. Ross AC, Judd S, Kumari M, et al. Vitamin D is linked to carotid intima-media thickness and immune reconstitu-tion in HIV-positive individuals. Antivir Ther. 2011;16(4): 555-563.
41. Kakalia S, Sochett EB, Stephens D, et al. Vitamin D supplementation and CD4 count in children infected with human immunodeficiency virus. J Pediatr. 2011; 159: 951-957.
42. Boonstra A, Barrat FJ, Crain C, et al. 1alpha, 25-dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol. 2001;167(9):4974-4978.
43. De St Groth B F, Landay AL. Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response? AIDS. 2008;22: 671-683.
44. Aandahl EM, Michaëlsson J, Moretto WJ, et al. Human CD4+CD25+regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol. 2004;78:2454-2459.
45. Sousa AE, Carneiro J, Meier-Schellersheim M, et al. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol. 2002;169:3400-3406.
46. Bang U, Kolte L, Hitz M, et al. Correlation of increases in 1, 25-dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV-1-infected males. HIV Clin Trials. 2012;13(3):162-170.
47. D'Ambrosio D, Cippitelli M, Cocciolo MG, et al. Inhibition of IL-12 production by 1, 25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest. 1998;101(1):252-262.
48. Shearer GM, Clerici M. Cytokine profiles in HIV type 1 disease and protection. AIDS Res Hum Retroviruses. 1998;14(suppl 2):S149-152.
49. Clerici M, Seminari E, Maggiolo F, et al. Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients. AIDS. 2002;16(13):1767-1773.